GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GT BIOPHARMA, INC. (GTBP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 23.34 thousand shares as of 2024-10-17, per its 10-K filed 2025-02-21.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-02-21
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2013-12-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2013-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2013-06-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2013-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 52.00K shares, a 83.84% decline from fiscal 2014.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 321.83K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2013 was 0.00 shares, a 100.00% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-10-17 | 23.34K shares 10-K · filed 2025-02-21 | ||||||
| 2023-05-31 | 83.33K shares 10-K · filed 2025-02-21 | ||||||
| 2023-05-15 | 16.67K shares 10-Q · filed 2024-11-14 | ||||||
| 2023-01-31 | 83.33K shares 10-K · filed 2025-02-21 | ||||||
| 2023-01-27 | 66.67K shares 10-Q · filed 2024-11-14 | ||||||
| 2016-12-31 | 0.00 shares 10-K/A · filed 2018-02-28 | ||||||
| 2015-12-31 | 52.00K shares 10-K/A · filed 2018-02-28 | ||||||
| 2014-12-31 | 321.83K shares 10-K/A · filed 2018-02-28 | 80.46M shares 10-K · filed 2015-03-31 | |||||
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2015-03-31 | 0.00 shares derived: sum of 3 quarters · filed 2015-03-31 | 0.00 shares 10-K · filed 2015-03-31 | |||
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17 | 0.00 shares derived: sum of 2 quarters · filed 2014-12-17 | 0.00 shares 10-Q · filed 2014-12-17 | 0.00 shares derived: sum of 4 quarters · filed 2015-01-08 | |||
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12 | 0.00 shares 10-Q · filed 2014-12-12 | 0.00 shares derived: sum of 3 quarters · filed 2015-01-08 | 0.00 shares derived: sum of 4 quarters · filed 2015-01-08 | |||
| 2013-03-31 | 0.00 shares 10-Q · filed 2014-12-10 | 0.00 shares derived: sum of 2 quarters · filed 2015-01-08 | 0.00 shares derived: sum of 3 quarters · filed 2015-01-08 | 0.00 shares derived: sum of 4 quarters · filed 2015-01-08 | |||
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-08 | 0.00 shares derived: sum of 2 quarters · filed 2015-01-08 | 0.00 shares derived: sum of 3 quarters · filed 2015-01-08 | 26.38M shares 10-K · filed 2015-01-08 | |||
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17 | 0.00 shares derived: sum of 2 quarters · filed 2014-12-17 | 26.38M shares 10-Q · filed 2014-12-17 | 28.77M shares derived: sum of 4 quarters · filed 2014-12-17 | |||
| 2012-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12 | 26.38M shares 10-Q · filed 2014-12-12 | 28.77M shares derived: sum of 3 quarters · filed 2014-12-12 | 29.31M shares derived: sum of 4 quarters · filed 2014-12-12 | |||
| 2012-03-31 | 26.38M shares 10-Q · filed 2014-12-10 | 28.77M shares derived: sum of 2 quarters · filed 2014-12-10 | 29.31M shares derived: sum of 3 quarters · filed 2014-12-10 | ||||
| 2011-12-31 | 2.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18 | 2.93M shares derived: sum of 2 quarters · filed 2014-11-18 | 4.45M shares 10-K · filed 2014-11-18 | ||||
| 2011-09-30 | 538.71K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-21 | 2.07M shares 10-Q · filed 2012-11-21 | |||||
| 2011-06-30 | 1.53M shares 10-Q/A · filed 2012-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |